Becton, Dickinson and Co (Becton, Dickinson and Co) Total Liabilities : $28,509.00 Mil (As of Mar. 2024)

View and export this data going back to 2017. Start your Free Trial

What is Becton, Dickinson and Co Total Liabilities?

Becton, Dickinson and Co's Total Liabilities for the quarter that ended in Mar. 2024 was $28,509.00 Mil.

Becton, Dickinson and Co's quarterly Total Liabilities declined from Sep. 2023 ($26,983.00 Mil) to Dec. 2023 ($26,941.00 Mil) but then increased from Dec. 2023 ($26,941.00 Mil) to Mar. 2024 ($28,509.00 Mil).

Becton, Dickinson and Co's annual Total Liabilities declined from Sep. 2021 ($30,203.00 Mil) to Sep. 2022 ($27,652.00 Mil) and declined from Sep. 2022 ($27,652.00 Mil) to Sep. 2023 ($26,983.00 Mil).

Becton, Dickinson and Co Total Liabilities Historical Data

The historical data trend for Becton, Dickinson and Co's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Becton, Dickinson and Co Total Liabilities Chart

Becton, Dickinson and Co Annual Data

Trend

Sep14

Sep15

Sep16

Sep17

Sep18

Sep19

Sep20

Sep21

Sep22

Sep23

Total Liabilities

Get a 7-Day Free Trial

30,683.00

30,247.00

30,203.00

27,652.00

26,983.00

Becton, Dickinson and Co Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Total Liabilities	Get a 7-Day Free Trial															28,703.00	27,079.00	26,983.00	26,941.00	28,509.00

Becton, Dickinson and Co Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

Becton, Dickinson and Co's Total Liabilities for the fiscal year that ended in Sep. 2023 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	6641	+	(14738	+	4581
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit)
	+	0	+	1023)
	=	26,983.00

Total Liabilities	=	Total Assets (A: Sep. 2023 )	-	Total Equity (A: Sep. 2023 )
	=	52780	-	25797
	=	26,983.00

Becton, Dickinson and Co's Total Liabilities for the quarter that ended in Mar. 2024 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	7327	+	(15995	+	4297
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit)
	+	0	+	890)
	=	28,509.00

Total Liabilities	=	Total Assets (Q: Mar. 2024 )	-	Total Equity (Q: Mar. 2024 )
	=	54157	-	25648
	=	28,509.00

Becton, Dickinson and Co Total Liabilities Related Terms

Thank you for viewing the detailed overview of Becton, Dickinson and Co's Total Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

Becton, Dickinson and Co (Becton, Dickinson and Co) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Becton, Dickinson and Co (NYSE:BDXA.PFD) » Definitions » Total Liabilities

Comparable Companies

Traded in Other Exchanges

BDX:USA BDX:Mexico 1BDX:Italy BOX:Germany B1DX34:Brazil

Address

1 Becton Drive, Franklin Lakes, NJ, USA, 07417-1880

Website

https://www.bd.com

Becton, Dickinson is the world's largest manufacturer and distributor of medical surgical products, such as needles, syringes, and sharps-disposal units. The company also manufactures pre-filled devices, diagnostic instruments and reagents, as well as flow cytometry and cell-imaging systems. BD Medical is nearly half of the total business, while BD Life Sciences (26% of estimated 2023 revenue) and BD Interventional (25%) account for the remainder. International revenue accounts for 43% of the company's business.